Survivin overexpression is closely linked to lung oncogenesis. Silencing of survivin gene by molecular antagonists has shown promise as novel anticancer strategies. DNA methylation is a critical epigenetic modification that silences gene transcription. In this study, we used a new methylated oligonucleotide, which mediates sequence-specific DNA methylation in cell, as a strategic alternative to survivin-targeting treatment, and investigated its efficacy in suppressing survivin expression and the consequent apoptotic induction potential in NCI-H460 cells. SurKex1, a methylated sense oligonucleotide, was shown to reduce specifically survivin mRNA expression and induce cell apoptosis. In addition, it has been supposed that the methylated oligonucleotide exerts its effect of gene silencing through the activation of DNA methyltransferase (DNMT1), but the exact mechanism is still unknown. Our data suggest for the first time that the SurKex1 exerts its down-regulatory effects on survivin expression through the activation of DNMT1.
Introduction
Lung cancer is one of the most malignant tumors with a very poor prognosis. It has two major subtypes based on histology, namely small cell lung cancer and non-small cell lung cancer (NSCLC), the latter accounting for 85% of all cases of lung cancer. More than 60% of all NSCLC patients have advanced or metastatic tumors at the time of diagnosis and are not amenable to surgery. 1 Despite advances in treatment over the past two decades, the overall survival of patients with NSCLC remains extremely poor. 2 Innovative treatment approaches that employ new agents targeting new molecules are urgently needed. In this regard, suppressing expression of survivin, an important molecule that is highly activated in a wide variety of human tumors, may hold promise. 3 Survivin is a newly discovered inhibitor of apoptosis, expressed in the G 2 /M phase of the cell cycle in a cellregulated manner. One of its most significant features is its differential expression in cancer versus normal tissues. Overexpression of survivin has oncogenic potential because it may overcome the G 2 /M checkpoint to enforce progression of cells through mitosis. More importantly, survivin inhibits downstream effector caspase-3 and caspase-7 receiving apoptotic stimulus. [4] [5] [6] [7] [8] [9] Recent studies have also shown that survivin expression levels correlate with oncogenesis, aggressiveness of tumors and poor clinical outcome in NSCLC. [10] [11] [12] [13] [14] [15] To target survivin overexpression as a cause of lung cancer, strategies have been designed to inhibit survivin synthesis with the hope of preventing or mitigating NSCLC. [16] [17] DNA methylation is a critical epigenetic modification that silences gene transcription. [18] [19] Yao et al. 20 have devised a method to inhibit transcriptional initiation by constructing short methylated oligonucleotides which induce DNA methylation at specific loci. In this study, we used SurKex1, a methylated sense oligonucleotide designed emulating the method of Yao et al.
20
, as an alternative strategy to target survivin and investigated its efficacy for the suppression of survivin expression and the consequent apoptotic induction potential in NCI-H460 cells.
We further studied the role of DNA methyltransferase (DNMT1) in the down-regulated expression of target gene mRNA by methylated oligonucleotides, and found that down-regulatory effects of SurKex1 on survivin expression in NCI-H460 cells may involve the activation of DNMT1.
Materials and methods

Cell culture and transfection
Human lung carcinoma cell lines (NCI-H460) were purchased from the Chinese Academy of Science (Shanghai, China) and maintained in RPMI-1640 medium (Gibco-BRL, Grand Island, NY) supplemented with 10% fetal bovine serum (Gibco-BRL RNA preparation and reverse transcription-PCR Total cytoplasmic RNA was isolated at stated times after transfection using Trizol reagent (Gibco BRL, Life Technologies, Grand Island, NY). Then 500 ng of total RNA was converted to cDNA in 10 ml and stored at À20 1C until use. PCR was carried out with cDNA using a specific primer pair for survivin: the sense primer was The activity of caspase-3 was assessed using caspase-3 colorimetric assay kits (Sigma-Aldrich, St Louis, MO). This assay is based on the detection of the colored p-nitroanaline (pNA) molecule following cleavage from the labeled substrate (DEVD-pNA). At different time points after transfections, NCI-H460 cells were trypsinzed, washed in 1 Â PBS and resuspended in lysis buffer (50 mM HEPES pH 7.4, 5 mM CHAPS and 5 mM DTT) for 20 min. Lysed cells were centrifuged at 15 000 g for 20 min and then equal amount of protein (B15 mg) from each sample was used to determine caspase-3 activity according to the manufacturer's instruction. The optical density was measured at 405 nm using a microplate reader (MULTISKAN EX PRIMARY EIA V.2.1-0).
Statistical analysis
Data were presented as mean ± s.d. or absolute numbers and percentages where indicated. For all measurements, as needed, an unpaired Student's t-test was employed to assess the statistical significance between treated groups and control groups. Differences were considered significant at Po0.05.
Results
Down-regulatory effects of SurKex1 on survivin expression levels
We first determined if a methylated oligonucleotideSurKex1 compounds would inhibit survivin gene expression in NCI-H460 cells, which contain a relatively high abundance of survivin. We carried out transfection of SurKex1 (2 mM) and a nonspecific oligonucleotide control-Random (2 mM) and PBS. The cells were, at 48 h after the start of transfection, examined by RT-PCR. As shown in Figure 1 , transfection with SurKex1 but not Random or PBS suppressed the expression of survivin. Similar results were also obtained when SurKex1 was tested in human lung adenocarcinoma-derived A549 cells.
We also examined how long the inhibition of survivin expression by SurKex1 lasted. NCI-H460 cells were incubated with 5 mM SurKex1 for 24 h (passage 1). Cells were collected and then seeded in the ratio of 1:2 in a new plate without further exposure to SurKex1 (passage 2). The above process was repeated until cell passage 4. As shown in Figure 2 , down-regulatory effects of SurKex1 on survivin expression was completely maintained in passage 3 but no further.
Survivin expression in NCI-H460 cell and A549 treated with 5-aza-2 0 -deoxycytidine To examine if DNMT1 are included in the downregulatory effects of SurKex1 on survivin expression, SurKex1-transfected cells were incubated with 1 mM 5-aza-2 0 -deoxycytidine (DNA methyltransferase inhibitor) for 48 h. As shown in Figure 1 , 5-aza-2 0 -deoxycytidine treatment induced survivin re-expression in SurKex1-transfected NCI-H460 cells and A549 cells. These results suggest that the downregulatory effects of SurKex1 on survivin expression is correlated with the activation of DNMT1.
Analysis of cell apoptosis and caspase-3 activity It has been reported that survivin could prevent apoptosis by targeting the terminal effectors caspase-3 and caspase-7, which act downstream in two major apoptotic pathways. 6, 9 In this experiment, we found that survivin expression decreased (Figure 1 ) and the caspase-3 activity increased ( Figure 3 ) with SurKex1 transfection in NCI-H460 cells. As SurKex1 can down-regulate caspase-3 activity, flow cytometry was used to quantify the changes in cell apoptosis after transfection with SurKex1. As shown in Figure 4a , NCI-H460 cells were treated with SurKex1 for 24, 48 and 72 h after the start of transfection, then analysed with flow cytometry using staining with Annexin-V-FITC and PI. SurKex1-treated cells revealed increased apoptotic ratio compared with Random-treated and PBS-treated ones. We also carried out a doseresponse experiment on cell apoptosis induction by SurKex1. NCI-H460 cells were incubated with an increasing concentration of Surkex1 or Random (0-3 mM) for 48 h after the start of transfection. Flow cytometry analysis found a significant dose-dependent increase in the apoptotic ratio in SurKex1-treated cells compared with Random-treated cells. Treatment with 1 and 3 mM doses of SurKex1 for 48 h resulted in 19 and 27% apoptotic cells, whereas those obtained from treatment with the same dosage of Random were 9 and 10%, respectively. (Figure 4b ).
Discussion
The balance between apoptosis and anti-apoptosis signal pathways has a role in the pathogenesis of a variety of cancers. It has been demonstrated that the inhibition of apoptosis promotes the mitotic progression in cancer cells. Apoptosis-based therapeutics are now tested in human clinical trials and have shown efficacy in preclinical animal models. As NSCLC cells express the highest level of survivin found in humor tumor, 4 inhibition of survivin would block the anti-apoptosis and mitotic progression in NSCLC. The molecular antagonists of survivin, including antisense, ribozymes, siRNA or dominant negative mutants have been successfully utilized to inhibit survivin expression or to interfere with its functions, inducing apoptosis and inhibiting tumor growth in vitro and in vivo, [21] [22] [23] [24] [25] [26] [27] [28] [29] As there are only two survivin alleles in each cell compared with hundreds Figure 2 Effect of passage number on expression of survivin in SurKex1-treated NCI-H460 cell. The NCI-H460 cells were seeded at a density of 1 Â 10 5 per well in a 24-well culture plate and were treated with 5 mM SurKex1 or 5 mM Random for 24 h, passaged in a 1:2 ratio. The subsequent passages were repeated in a similar manner. Oligonucleotides were encapsulated in liposomes before application. RNA was isolated from sample wells and assayed for survivin and actin mRNA by RT-PCR. S, SurKex1; R, Random. P1, 1st passage cell, P2, 2nd passage cell, P3, 3rd passage cell and P4, 4th passage cell. of thousands of survivin mRNA molecules, an antigene strategy at the transcriptional level probably possesses advantage over antisense, RNAi or ribozyme-based techniques. Recently, Yao et al. 20 have devised a method to inhibit transcriptional initiation by constructing short methylated oligonucleotides which induce DNA methylation at specific loci. The methylated oligonucleotide combines a DNA targeting mechanism and methylationinducing trigger in a single oligonucleotide construct composed of a guiding element and an inactivating element. The guiding element is a short sense oligonucleotide complementary to the DNA template strand. It functions to guide the inactivating element to a specific nucleotide sequence, typically within the proximal promoter, of the target gene. When bound to the target, the inactivating element can alter the epigenome by inducing methylation of CpG dinucleotides in a previously unmethylated target DNA strand. This change in methylation correlates with the down-regulated expression of target gene mRNA. Therefore, this methylation-inducing methodology can be used as a powerful approach to silence mammalian gene expression for gene function studies and cancer therapy.
In our study, we used this technology as an alternative strategy to target survivin and investigated its efficacy in suppressing survivin expression and the consequent apoptotic induction potential in NCI-H460 cells. We designed a methylated oligonucleotide, SurKex1, that can bind to the promoter region of human survivin and lead to the site-and sequence-specific methylation of the survivin promoter (data not shown). Our results show that when incubated with NSCLC cells for 48 h, SurKex1 selectively inhibited survivin expression but the nonspecific oligonucleotide control-Random did not, and neither did PBS. In addition, it is reported that the effect of methylation-inducing gene silence may be greatly different from antisense oligonucleotide. [18] [19] [20] Theoretically, the epigenetic mark (DNA methylation) imposed is very stable in the genome and heritable through cell divisions. In our studies, we found that down-regulatory effects of SurKex1 on survivin expression persisted only up to passage 3 but weakened drastically in passage 4 after termination of SurKex1 transfection (Figure 2 ). This phenomenon, re-expression of a gene silenced with oligonucleotide-induced methylation, was also observed by Yao et al. and Ishii et al. 20, 30 According to a speculation by Yao et al. 20 , a likely cause of re-expression is demethylation of the target gene promoter or a marked survival advantage in those cells escaping oligonucleotideinduced methylation silencing of mitogenic gene, which will ultimately become the predominant cell type and resume the target gene transcription. The exact mechanism of this re-expression remains unclear.
Although it has been supposed that the methylated oligonucleotide exerts its effect of gene silencing and methylation inducing through the activation of DNMT1, the exact mechanism is still unknown. In this study, we incubated cells with the combination of SurKex1 and 5-aza-2 0 -deoxycytidine for 48 h. As shown in Figure 1 , treatment of NCI-H460 and A549 cells with the demethylating agent 5-aza-2 0 -deoxycytidine reactivated survivin mRNA expression. Our data suggest, for the first time, that the downregulatory effects of SurKex1 on survivin expression is through the activation of DNMT1.
Caspase-3, a protease that has a key role in a proteolytic cascade within the apoptosis signal pathway, is activated by numerous cell death-inducing signals. Like other IAP proteins, survivin directly inhibits caspase-3, essential for suppression of caspase-mediated cleavage of centrosome-associated p21. 31 Survivin also binds to the IAP inhibitor Smac/Diablo, which may free other IAP members to suppress caspases. 32 In our studies, we were able to witness increased caspase-3-like protease and apoptotic ratio in NCI-H460 cells by transfection of SurKex1. Treatment of cells with 1 and 3 mM doses of SurKex1 for 48 h resulted in 19 and 27% apoptosis respectively, much higher than with Random (Figures 3,  4) . Our results are in agreement with the previous findings indicating that survivin inhibitors led to increased apoptotic cell ratio. The NCI-H460 cells were seeded at a density of 1 Â 10 6 per well in a 12-well culture plate and were treated with 2 mM SurKex1 or Random. At 24, 48 and 72 h after treatment, cells were harvested for detection of apoptosis by staining with Annexin V and FACS analysis. Each point is the average of triplicate determinants. The differences between SurKex1 group and Random group were tested by unpaired Student's t-test. **Po0.001, # P ¼ 0.06; (b) The NCI-H460 cells were seeded at a density of 1 Â 10 6 per well in a 12-well culture plate and were treated with an increasing concentration of SurKex1 or Random (0-3 mM), 20 mM paclitaxel for 48 h after the start of transfection, washed and then harvested. The apoptosis was analyzed by FACS. Each point is the average of triplicate determinants. The differences between SurKex1 group and Random group were tested by unpaired Student's t-test. **P ¼ 0.0002, # P ¼ 0.06.
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In summary, we have demonstrated that down-regulation of survivin expression by the methylated oligonucleotide SurKex1 facilitates apoptosis. Also shown is that DNAM1 likely has an important role in the downregulation of survivin mRNA expression levels by SurKex1, which may be an important mechanism for the inactivation of genes by site-specific methylationinducing oligonucleotide.
